CA2249390A1 - Peptides reconnus par des lymphocytes cytotoxiques specifiques du melanome restreints par a1, a2 et a3, leurs utilisations - Google Patents

Peptides reconnus par des lymphocytes cytotoxiques specifiques du melanome restreints par a1, a2 et a3, leurs utilisations

Info

Publication number
CA2249390A1
CA2249390A1 CA002249390A CA2249390A CA2249390A1 CA 2249390 A1 CA2249390 A1 CA 2249390A1 CA 002249390 A CA002249390 A CA 002249390A CA 2249390 A CA2249390 A CA 2249390A CA 2249390 A1 CA2249390 A1 CA 2249390A1
Authority
CA
Canada
Prior art keywords
melanoma
specific
cytotoxic lymphocytes
uses therefor
restricted cytotoxic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002249390A
Other languages
English (en)
Other versions
CA2249390C (fr
Inventor
Craig L. Slingluff
Donald F. Hunt
Jeffrey Shabanowitz
Andrea L. Cox
Victor H. Engelhard
David Kittlesen
Jonathan Skipper
Ronald C. Hendrikson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UVA Licensing and Ventures Group
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2249390A1 publication Critical patent/CA2249390A1/fr
Application granted granted Critical
Publication of CA2249390C publication Critical patent/CA2249390C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0055—Oxidoreductases (1.) acting on diphenols and related substances as donors (1.10)
    • C12N9/0057—Oxidoreductases (1.) acting on diphenols and related substances as donors (1.10) with oxygen as acceptor (1.10.3)
    • C12N9/0059—Catechol oxidase (1.10.3.1), i.e. tyrosinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/46449—Melanoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/46449—Melanoma antigens
    • A61K39/464492—Glycoprotein 100 [Gp100]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA002249390A 1996-03-19 1997-03-17 Peptides reconnus par des lymphocytes cytotoxiques specifiques du melanome restreints par a1, a2 et a3, leurs utilisations Expired - Fee Related CA2249390C (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US1397296P 1996-03-19 1996-03-19
US60/013,972 1996-03-19
US2762796P 1996-10-04 1996-10-04
US60/027,627 1996-10-04
PCT/US1997/004958 WO1997034613A1 (fr) 1996-03-19 1997-03-17 Peptides reconnus par des lymphocytes cytotoxiques specifiques du melanome restreints par a1, a2 et a3, leurs utilisations

Publications (2)

Publication Number Publication Date
CA2249390A1 true CA2249390A1 (fr) 1997-09-25
CA2249390C CA2249390C (fr) 2007-12-18

Family

ID=26685490

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002249390A Expired - Fee Related CA2249390C (fr) 1996-03-19 1997-03-17 Peptides reconnus par des lymphocytes cytotoxiques specifiques du melanome restreints par a1, a2 et a3, leurs utilisations

Country Status (4)

Country Link
EP (1) EP0921805A4 (fr)
AU (1) AU712820B2 (fr)
CA (1) CA2249390C (fr)
WO (1) WO1997034613A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2763071B1 (fr) * 1997-05-07 2003-05-16 Centre Nat Rech Scient Analogues peptidiques, et leurs utilisations notamment dans des compositions pharmaceutiques et pour le diagnostic
EP1161147A4 (fr) * 1998-12-24 2002-07-24 New York Medical College Mimetiques peptidiques utiles pour traiter des maladies
JP2002536008A (ja) * 1999-02-11 2002-10-29 ジェンザイム・コーポレーション 抗原ペプチドコンカテマー
JP4540033B2 (ja) 1999-10-22 2010-09-08 サノフィ パストゥール リミテッド 腫瘍抗原に対する免疫応答を誘発および／または増強する方法
WO2001032193A1 (fr) * 1999-10-29 2001-05-10 Argonex Pharmaceuticals Peptides stimulant les lymphocytes t cytotoxiques, utilisables en prevention, traitement et diagnostic de melanome
US6861234B1 (en) * 2000-04-28 2005-03-01 Mannkind Corporation Method of epitope discovery
CA2410865A1 (fr) * 2000-05-31 2001-12-06 Genzyme Corporation Composes therapeutiques pour le cancer de l'ovaire
AU2002249917A1 (en) * 2001-01-04 2002-08-12 Yale University Induction of immune responses to isoaspartyl-modified antigens
EP2314712B1 (fr) 2001-11-07 2014-01-08 Mannkind Corporation Vecteurs d´expression codant pour des épitopes d´antigènes et procédés permittant leur conception
DE102005041616B4 (de) * 2005-09-01 2011-03-17 Johannes-Gutenberg-Universität Mainz Melanom-assoziierte MHC Klasse I assoziierte Oligopeptide und für diese kodierende Polynukleotide und deren Verwendungen
EP2232258A4 (fr) 2007-12-05 2011-01-05 Govt Of The U S A As Represented By The Secretary Of The Dept Of Health & Human Services Quantification de proteines virales ameliorees et controle de la qualite des vaccins

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0006916B1 (fr) * 1977-09-28 1981-07-08 National Research Development Corporation Préparations immunoligiques contenant MHC antigens et leur production
JPH08506100A (ja) * 1992-12-22 1996-07-02 ルードヴィッヒ・インスティテュート・フォア・キャンサー・リサーチ Ｈｌａ−ａ２／チロシナーゼペプチド抗原を発現する異常細胞を有する個体の検出と治療
US6660276B1 (en) * 1994-02-16 2003-12-09 The University Of Virginia Patent Foundation Peptides recognized by melanoma-specific cytotoxic lymphocytes, and uses therefor
US5709995A (en) * 1994-03-17 1998-01-20 The Scripps Research Institute Hepatitis C virus-derived peptides capable of inducing cytotoxic T lymphocyte responses
US6558671B1 (en) * 1997-01-30 2003-05-06 The University Of Virginia Patent Foundation Cysteine-depleted peptides recognized by A3-restricted cytotoxic lymphocytes, and uses therefor

Also Published As

Publication number Publication date
EP0921805A4 (fr) 2002-06-26
AU712820B2 (en) 1999-11-18
WO1997034613A1 (fr) 1997-09-25
AU2424397A (en) 1997-10-10
CA2249390C (fr) 2007-12-18
EP0921805A1 (fr) 1999-06-16

Similar Documents

Publication Publication Date Title
GB9626484D0 (en) Helicobacter pylori antigenic protein preparation and immunoassays
CA2118928A1 (fr) Conjugues saponine-antigene et leur utilisation
CA2189882A1 (fr) Vaccins contre le papillomavirus
EP1564824A3 (fr) Composition de conversion d'énergie
AU1750097A (en) Highly concentrated, lyophilized, and liquid factor ix formulations
CA2267072A1 (fr) Anticorps anti-hm1.24 humain reconstitue
EP0592202A3 (fr) D-ketohexose-3-épimerase, sa préparation et son utilisation.
AU4556597A (en) Recombinant mva virus expressing dengue virus antigens, and the use thereof in vaccines
WO1995013297A3 (fr) Compositions immunogenes ameliorees agissant contre la gastrine humaine 17
CA2249390A1 (fr) Peptides reconnus par des lymphocytes cytotoxiques specifiques du melanome restreints par a1, a2 et a3, leurs utilisations
CA2042236A1 (fr) Epitopes ayant un effet seroreactif sur les proteines du papillomavirus humain (hpv) 18
CA2182889A1 (fr) Peptides reconnus par les lymphocytes cytotoxiques specifiques du melanome, et applications
AU662213B2 (en) Turbine and turbocharger using the same
AU1598500A (en) Hla-a2 and hla-dr specific peptide epitopes from the melanoma antigen trp2
AU7495796A (en) Novel oligopeptides, the preparation and use thereof
AU1086888A (en) Primary biliary cirrhosis autoantigen
WO1996002572A3 (fr) Sequence polypeptidique antigenique du facteur viii, fragments et/ou epitopes de celle-ci
AU2913400A (en) Mage-3 derived immunogenic peptides presented by mhc of class ii and the use thereof
AU2000275748A1 (en) Hla-a2.1 binding peptides and their uses
WO1992017439A3 (fr) Diaminomesitylene perfluoroalkyle et polyimides obtenus avec celui-ci
AU2001273950A1 (en) Antibodies against native gp96, production and use thereof
RU95110526A (ru) Вакцина против пневмококковой инфекции
ZA98587B (en) A novel antigen from P. aeruginosa, and its use in medicine.
AU4863490A (en) Polypeptides, antigens or vaccines protective against babesiosis
AU8113691A (en) The class ii protein of the outer membrane of neisseria meningitidis having immunologic carrier and enhancement properties, and vaccines containing same

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed